Evidence map›Paper›PMID 41393976›Full record

ArticleiScience2025

Monoclonal antibodies against human TMPRSS2 prevent infection by any SARS-CoV-2 variant.

Michishige Harada, Takehisa Matsumoto, Mizuki Yamamoto, Jin Goda, Akiko Idei, Kenichi Ohtaki, Natsuki Kojima, Natsumi Yoneda, Kosuke Miyauchi, Kazushige Katsura and 25 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Michishige HaradaDrug Discovery Antibody Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Takehisa MatsumotoDrug Discovery Structural Biology Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Mizuki YamamotoResearch Center for Asian Infectious Diseases, Institute for Medical Sciences, University of Tokyo, Tokyo 108-8639, Japan.
Jin GodaResearch Center for Asian Infectious Diseases, Institute for Medical Sciences, University of Tokyo, Tokyo 108-8639, Japan.
Akiko IdeiDrug Discovery Seed Compounds Exploratory Unit, RIKEN Center for Sustainable Resource Science, Wako, Saitama 351-0198, Japan.
Kenichi OhtakiDrug Discovery Antibody Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Natsuki KojimaDrug Discovery Antibody Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Natsumi YonedaDrug Discovery Antibody Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Kosuke MiyauchiLaboratory for Infectious Disease and Immunology, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Kazushige KatsuraDrug Discovery Structural Biology Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Mariko IkedaDrug Discovery Structural Biology Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Kazuharu HanadaDrug Discovery Structural Biology Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Yoshiko Ishizuka-KatsuraLaboratory for Protein Functional and Structural Biology, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Toshiaki HosakaDrug Discovery Structural Biology Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Tamao HisanoLaboratory for Protein Functional and Structural Biology, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Toshie KaizukaDrug Discovery Seed Compounds Exploratory Unit, RIKEN Center for Sustainable Resource Science, Wako, Saitama 351-0198, Japan.
Takako YamamotoLaboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Masashi MatsudaLaboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Manabu NakayamaLaboratory of Medical Omics Research, Department of Frontier Research and Development, Kazusa DNA Research Institute, Kisarazu, Chiba 292-0818, Japan.
Akiko Sugimoto-IshigeLaboratory for Infectious Disease and Immunology, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Machie SakumaLaboratory for Infectious Disease and Immunology, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Rina HashimotoCenter for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo Ward, Kyoto 606-8507, Japan.
Kazuo TakayamaCenter for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo Ward, Kyoto 606-8507, Japan.
Misako NakayamaDepartment of Pathology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Cong Thanh NguyenDepartment of Pathology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Hirohito IshigakiDepartment of Pathology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Yasushi ItohDepartment of Pathology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Yoshinobu HashizumeRIKEN Program for Drug Discovery and Medical Technology Platforms, RIKEN TRIP Headquarters, Yokohama 230-0045, Japan.
Minoru YoshidaDrug Discovery Seed Compounds Exploratory Unit, RIKEN Center for Sustainable Resource Science, Wako, Saitama 351-0198, Japan.
Yasushi KawaguchiResearch Center for Asian Infectious Diseases, Institute for Medical Sciences, University of Tokyo, Tokyo 108-8639, Japan.
Makoto TakedaDepartment of Microbiology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.
Haruhiko KosekiLaboratory for Infectious Disease and Immunology, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Mikako ShirouzuDrug Discovery Structural Biology Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Jun-Ichiro InoueDivision of Molecular Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Takashi SaitoDrug Discovery Antibody Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transmembrane serine protease 2 (TMPRSS2) plays a critical role in SARS-CoV-2 infection by priming the viral Spike (S) protein for host cell entry and thus represents a potential target for COVID-19 therapy. Here monoclonal antibodies (mAbs) against human TMPRSS2 were established for therapeutic application.

Indexed as

Health sciencesImmunologyVirology

Identifiers

PMID41393976
PMCPMC12696409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.